Skip to content

Comprehensive analysis encompassing genomic, clinicopathological and radiologic features in early stage lung cancer

Comprehensive analysis encompassing genomic, clinicopathological and radiologic features in early stage lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038717
Enrollment
Unknown
Registered
2020-09-29
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Review group:retrospective analysis
Prospective group:case-observational study

Sponsors

Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 85 Years

Inclusion criteria

Inclusion criteria: Review group: 1. Patients aged 20 to 85 years old; 2. Patients who underwent pulmonary lesions' resection and postoperative pathology confirmed it as early stage lung cancer. 3. Relevant materials for analysis were available. Prospective group 1.Patients should be younger than 85 years old and older than 20 years old. 2.Patients who plans to undergo pulmonary lesions' resection and postoperative pathology confirms it as early stage lung cancer. 3.Willingness to voluntarily participate in the clinical trail and sign informed consent.

Exclusion criteria

Exclusion criteria: Review group 1.The postoperative pathologic diagnosis was not NSCLC. 2.Postoperative pathologic stage was staged IB or more aggressive. 3.Patients who are judged unsuitable for clinical trail participation by the principle investigator. Prospective group 1.Patients who had a past history of tumors of other systems. 2.Relevant materials for analysis were unavailable. 3.Patients who are judged unsuitable for clinical trail participation by the principle investigator.

Design outcomes

Primary

MeasureTime frame
pathology results;radiologic characters;driver mutations;

Secondary

MeasureTime frame
clinical data;

Countries

China

Contacts

Public ContactFenglei Yu

Second Xiangya Hospital of Central South University

yufenglei@csu.edu.cn+86 13755182999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026